Non-specific low back pain: principles and algorithms for successful management of patients in real clinical practice
Open Access
- 4 July 2023
- journal article
- research article
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (3) , 85-94
Abstract
Non-specific low back pain (LBP) occurs in most people at least once in a lifetime. In city polyclinics, every fourth patient complains of LBP. During the COVID-19 pandemic, the prevalence of acute non-specific LBP and chronic LBP have increased due to physical inactivity, chronic stress, and anxiety. Musculoskeletal LBP is the second most common cause of disability. In this regard, it is important to consider modern principles for the diagnosis and treatment of non-specific LBP. Diagnostic algorithms, “red flags” (dangerous symptoms), “yellow flags” (chronification factors) in LBP are discussed. Own clinical cases of patients with LBP with “red flags” are presented. Effective drug and non-drug methods of treatment of LBP are considered: patient education, kinesiotherapy, cognitive-behavioral therapy, manual therapy, the use of non-steroidal anti-inflammatory drugs, muscle relaxants. The role of aceclofenac and tolperisone in the treatment of LBP is discussed, clinical studies data on the efficacy and safety of these drugs in pain syndromes are presented. We present our own clinical observation of the successful management of a patient with chronic non-specific LBP.Keywords
This publication has 35 references indexed in Scilit:
- Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013The Lancet, 2015
- Basic Aspects of the Pharmacodynamics of Tolperisone, A Widely Applicable Centrally Acting Muscle RelaxantThe Open Medicinal Chemistry Journal, 2014
- Aceclofenac in rheumatology: The golden meanModern Rheumatology Journal, 2013
- Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinationsGut, 2006
- Aceclofenac in the management of inflammatory painExpert Opinion on Pharmacotherapy, 2004
- Upper Gastrointestinal Bleeding Associated with the Use of NSAIDsDrug Safety, 2004
- Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenacClinical Pharmacology & Therapeutics, 2003
- A double-blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back painClinical Rheumatology, 2003
- Patient and Physician Satisfaction with Aceclofenac: Results of the European Observational Cohort Study (Experience with Aceclofenac for Inflammatory Pain in Daily Practice)Current Medical Research and Opinion, 2002
- Evaluation of Sedative Effects of Single and Repeated Doses of 50 mg and 150 mg Tolperisone Hydrochloride. Results of a Prospective, Randomized, Double-Blind, Placebo-Controlled TrialPharmacopsychiatry, 1998